| NCT ID | NCT07510087 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Marc Toeteberg-Harms |
| Condition | Glaucoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 5,000 participants |
| Start Date | 2024-12-30 |
| Primary Completion | 2026-11-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 5,000 participants in total. It began in 2024-12-30 with a primary completion date of 2026-11-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Subjects with a diagnosis of glaucoma will be handed out different quality of life related questionnaires and their score will be evaluated at baseline and 3-6 months after treatment or surgery was initiated/performed.
Eligibility Criteria
Inclusion: * diagnosis of glaucoma (open- as well as closed-angle glaucoma, primary and secondary glaucomas) * 18 years of age or older with no upper limit * male and female subjects Exclusion: * absence of a diagnosis of glaucoma * less than 18 years of age
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07510087 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Glaucoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07510087 currently recruiting?
Yes, NCT07510087 is actively recruiting participants. Contact the research team at marc-toeteberg-harms@uiowa.edu for enrollment information.
Where is the NCT07510087 trial being conducted?
This trial is being conducted at Iowa City, United States.
Who is sponsoring the NCT07510087 clinical trial?
NCT07510087 is sponsored by Marc Toeteberg-Harms. The trial plans to enroll 5,000 participants.